Basis: Trailing twelve months (TTM), to the latest fiscal quarter end. Source: stored company filings and market data; unavailable inputs remain N/A.
Is the return on equity (ROE) high or low?
The return on equity (ROE) of 3.03% is 84% above its 5-year average of 1.65%, around the middle of its 5-year range (-2.90%–7.22%).
As of the fiscal period ended Tuesday, June 30, 2026. 82.79% above its 12-month average of 1.66%.
Trailing-twelve-month return on equity at each fiscal quarter end; no daily interpolation. Q2 FY2026 (2026-06-30): 3.03%.
RETURN ON EQUITY (ROE)
3.03%
RETURN ON EQUITY (ROE) AVG TTM
1.66%
RETURN ON EQUITY (ROE) AVG 3Y
-0.04%
RETURN ON EQUITY (ROE) AVG 5Y
1.65%
RETURN ON EQUITY (ROE) AVG 10Y
2.83%
RETURN ON EQUITY (ROE) AVG 15Y
3.85%
RETURN ON EQUITY (ROE) AVG 20Y
4.49%
CURRENT VS TTM AVG
+82.79%
CURRENT VS 3Y AVG
+7048.37%
CURRENT VS 5Y AVG
+83.92%
CURRENT VS 10Y AVG
+6.95%
CURRENT VS 15Y AVG
-21.37%
CURRENT VS 20Y AVG
-32.64%
SECTOR MEDIAN · HEALTHCARE
-42.01%
median of 746 covered companies
CURRENT VS SECTOR MEDIAN
+107.20%
vs the sector median at left
Omnicell, Inc.
Market Cap
$1.60B
Return on Equity (ROE)
3.03%
TTM Avg
1.66%
3Y Avg
-0.04%
5Y Avg
1.65%
Market Cap
$1.60B
Return on Equity (ROE)
-67.40%
TTM Avg
-53.05%
3Y Avg
2.62%
5Y Avg
2.10%
Market Cap
$1.62B
Return on Equity (ROE)
-57.97%
TTM Avg
-51.00%
3Y Avg
-97.84%
5Y Avg
-100.56%
Market Cap
$1.62B
Return on Equity (ROE)
17.72%
TTM Avg
5.08%
3Y Avg
0.03%
5Y Avg
-3.88%
Market Cap
$1.62B
Return on Equity (ROE)
-6.27%
TTM Avg
-14.95%
3Y Avg
-10.20%
5Y Avg
-10.20%
Market Cap
$1.64B
Return on Equity (ROE)
N/A
TTM Avg
-1058.20%
3Y Avg
-465.87%
5Y Avg
-348.95%
Market Cap
$1.54B
Return on Equity (ROE)
28.97%
TTM Avg
13.25%
3Y Avg
22.73%
5Y Avg
32.77%
Market Cap
$1.54B
Return on Equity (ROE)
-77.83%
TTM Avg
1723.94%
3Y Avg
818.18%
5Y Avg
546.13%
Market Cap
$1.55B
Return on Equity (ROE)
-60.17%
TTM Avg
-20.40%
3Y Avg
-40.27%
5Y Avg
-36.46%
| NAME | MARKET CAP | RETURN ON EQUITY (ROE) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Omnicell, Inc. (OMCL) | $1.60B | 3.03% | 1.66% | -0.04% | 1.65% |
| Kestra Medical Technologies, Ltd. (KMTS)vs › | $1.60B | -67.40% | -53.05% | 2.62% | 2.10% |
| Ocular Therapeutix, Inc. (OCUL)vs › | $1.62B | -57.97% | -51.00% | -97.84% | -100.56% |
| ANI Pharmaceuticals, Inc. (ANIP)vs › | $1.62B | 17.72% | 5.08% | 0.03% | -3.88% |
| Septerna Inc (SEPN)vs › | $1.62B | -6.27% | -14.95% | -10.20% | -10.20% |
| Alphatec Holdings, Inc. (ATEC)vs › | $1.64B | N/A | -1058.20% | -465.87% | -348.95% |
| Innoviva, Inc. (INVA)vs › | $1.54B | 28.97% | 13.25% | 22.73% | 32.77% |
| uniQure N.V. (QURE)vs › | $1.54B | -77.83% | 1723.94% | 818.18% | 546.13% |
| Stoke Therapeutics, Inc. (STOK)vs › | $1.55B | -60.17% | -20.40% | -40.27% | -36.46% |
| Syndax Pharmaceuticals, Inc. (SNDX)vs › | $1.54B | -1462.12% | -276.13% | -155.50% | -107.48% |
ROE
3.0%
ROA
2.0%
ROE = Net Income / Total Shareholders' Equity
Return on equity measures how efficiently a company generates profit from shareholders' equity. Higher ROE indicates better capital efficiency.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | RETURN ON EQUITY (ROE) |
|---|---|
| 2026-06-30 | 3.03% |
| 2026-03-31 | 1.63% |
| 2025-12-31 | 0.17% |
| 2025-09-30 | 1.63% |
| 2025-06-30 | 1.83% |
| 2025-03-31 | 1.69% |
| 2024-12-31 | 1.01% |
| 2024-09-30 | -1.44% |
| 2024-06-30 | -1.73% |
| 2024-03-31 | -1.77% |
| 2023-12-31 | -1.71% |
| 2023-09-30 | -2.90% |
| 2023-06-30 | -1.99% |
| 2023-03-31 | -1.54% |
| 2022-12-31 | 0.50% |
| 2022-09-30 | 4.23% |
| 2022-06-30 | 5.54% |
| 2022-03-31 | 6.69% |
| 2021-12-31 | 6.79% |
| 2021-09-30 | 7.22% |
| 2021-06-30 | 5.67% |
| 2021-03-31 | 3.46% |
| 2020-12-31 | 3.33% |
| 2020-09-30 | 4.13% |
| 2020-06-30 | 5.53% |
| 2020-03-31 | 7.90% |
| 2019-12-31 | 7.26% |
| 2019-09-30 | 6.69% |
| 2019-06-30 | 6.17% |
| 2019-03-31 | 5.24% |
| 2018-12-31 | 5.55% |
| 2018-09-30 | 7.63% |
| 2018-06-30 | 7.02% |
| 2018-03-31 | 6.20% |
| 2017-12-31 | 4.28% |
| 2017-09-30 | -0.43% |
| 2017-06-30 | -1.73% |
| 2017-03-31 | -2.23% |
| 2016-12-31 | 0.14% |
| 2016-09-30 | 1.89% |
| 2016-06-30 | 3.43% |
| 2016-03-31 | 5.86% |
| 2015-12-31 | 7.64% |
| 2015-09-30 | 8.26% |
| 2015-06-30 | 7.91% |
| 2015-03-31 | 7.56% |
| 2014-12-31 | 7.82% |
| 2014-09-30 | 7.42% |
| 2014-06-30 | 7.56% |
| 2014-03-31 | 7.34% |
| 2013-12-31 | 6.88% |
| 2013-09-30 | 6.34% |
| 2013-06-30 | 6.55% |
| 2013-03-31 | 5.35% |
| 2012-12-31 | 5.26% |
| 2012-09-30 | 4.99% |
| 2012-06-30 | 3.78% |
| 2012-03-31 | 4.15% |
| 2011-12-31 | 3.67% |
| 2011-09-30 | 2.49% |
| 2011-06-30 | 1.92% |
| 2011-03-31 | 1.71% |
| 2010-12-31 | 1.84% |
| 2010-09-30 | 1.82% |
| 2010-06-30 | 1.70% |
| 2010-03-31 | 1.31% |
| 2009-12-31 | 0.18% |
| 2009-09-30 | 1.31% |
| 2009-06-30 | 2.20% |
| 2009-03-31 | 3.02% |
| 2008-12-31 | 5.45% |
| 2008-09-30 | 10.84% |
| 2008-06-30 | 13.33% |
| 2008-03-31 | 19.10% |
| 2007-12-31 | 17.00% |
| 2007-09-30 | 14.72% |
| 2007-06-30 | 13.99% |
| 2007-03-31 | 14.02% |
| 2006-12-31 | 12.42% |
| 2006-09-30 | 10.67% |
| 2006-06-30 | 9.56% |
| 2006-03-31 | 7.84% |
| 2005-12-31 | -3.75% |
| 2005-09-30 | -3.21% |
| 2005-06-30 | 0.30% |
| 2005-03-31 | 5.01% |
| 2004-12-31 | 19.74% |
| 2004-09-30 | 22.04% |
| 2004-06-30 | 22.94% |
| 2004-03-31 | 22.01% |
| 2003-12-31 | 21.02% |
| 2003-09-30 | -6.32% |
| 2003-06-30 | -32.91% |
